Expert consensus document on β-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology

European Heart Journal

Volumn 25, Issue 15, 2004, Pages 1341-1362

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; ALPRENOLOL; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; BUCINDOLOL; CARTEOLOL; CARVEDILOL; CELIPROLOL; CIMETIDINE; DILTIAZEM; ESMOLOL; HYDRALAZINE; LABETALOL; METOPROLOL; NADOLOL; NEBIVOLOL; NEVIBOLOL; OXPRENOLOL; PENBUTOLOL; PINDOLOL; PROPRANOLOL DERIVATIVE; SOTALOL; TIMOLOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; XAMOTEROL;

AORTA DISSECTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DEPRESSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FATIGUE; HALF LIFE TIME; HEADACHE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; INSOMNIA; ISCHEMIC HEART DISEASE; LONG QT SYNDROME; LUNG DISEASE; META ANALYSIS; METABOLIC DISORDER; MITRAL VALVE PROLAPSE; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS TACHYCARDIA; SLEEP DISORDER; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; TREATMENT CONTRAINDICATION;

ADRENERGIC BETA-ANTAGONISTS; ARRHYTHMIA; DEATH, SUDDEN, CARDIAC; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PRACTICE GUIDELINES;

EID: 3442901436     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2004.06.002     Document Type: Review

References (229)

1. Cruickshank J.M., Prichard B.N.C. Beta-adrenoceptors. Cruickshank J.M., Prichard B.N.C. Beta-blockers in clinical practice. 1996;9-86 Churchill Livingstone, London
2. Tamargo J.L., Delpón E. Optimisation of β-blockers pharmacology. J. Cardiovasc. Pharmacol. 16(Suppl. 5):1990;S8-S10
3. Frishman W.H., Lazar E.J., Gorodokin G. Pharmacokinetic optimisation of therapy with beta-adrenergic-blocking agents. Clin. Pharmacokinet. 20:1991;311-318
4. Frishman W.H. Carvedilol. N. Engl. J. Med. 339:1998;1759-1765
5. Benfield P., Sorkin E.M. Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs. 33:1987;392-412
6. Bristow M.R. Pathophysiologic and pharmacologic rationale for clinical management of chronic hart failure with beta-blocking agents. Am. J. Cardiol. 71:1993;12C-22C
7. Bouzamondo A., Hulot J.S., Sanchez P., et al. Beta-blocker treatment in heart failure. Fundam. Clin. Pharmacol. 15:2001;95-109
8. Waagstein F. Beta-blockers in congestive heart failure: the evolution of a new treatment concept-mechanism of action and clinical implications. J. Clin. Basic Cardiol. 5:2002;215-223
9. Man in't Veld A.J., van der Meiracker A., Schalekamp M.A. The effect of beta-adrenoceptor antagonists on total peripheral resistance. J. Cardiovasc. Pharmacol. 8(Suppl. 4):1986;S49-S60
10. Frishman W.H. Multifactorial actions of beta-adrenergic-blocking drugs in ischemic heart disease: current concepts. Circulation. 67(Suppl. I):1983;I-11-8
11. Opie L.H. Effect of beta-adrenergic blockade on biochemical and metabolic response to exercise. Am. J. Cardiol. 55:1985;95D
12. Kukin M.L., Kalman J., Charney R., et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 102:1999;2646-2651
13. Cleland J.G., Dargie H.J. Arrhythmias, catecholamines and electrolytes. Am. J. Coll. Cardiol. 62:1988;55-59
14. Shizukuda Y., Buttrick P.M., Geenen D., et al. Beta-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am. J. Physiol. 275:1998;961-968
15. Lowes B.D., Gilbert E.M., Abraham W.T., et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N. Engl. J. Med. 346:2002;1357-1365
16. Hjalmarson Å., Elmfeldt D., Herlitz J., et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. ii:1981;823-887
17. Hjalmarson Å, Goldstein S, Fagerberg B et al. for the MERIT-HF Study Group: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The metoprolol CR/Xl randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1293-302
18. Thadani U., Whitsett T.L. Beta-adrenergic-blockers and intermittent claudication: time for reappraisal. Arch. Int. Med. 151:1991;1705-1707
19. Radack K., Deck C. β-Adrenergic blocker therapy does not worsen intermitent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch. Int. Med. 151:1991;1769-1776
20. Kjekshus J., Gilpin E., Gali G., et al. Diabetic patients and beta blockers after acute myocardial infarction. Eur. Heart J. 11:1990;43-50
21. Gottlieb S., McCarter R., Vogel R. Effect of beta-blockade on mortality among high risk patients after myocardial infarction. N. Engl. J. Med. 338:1998;489-497
22. Poole-Wilson P. COMET study. European Congress of Cardiology. Vienna, September 2003
23. Chen J., Radford M.J., Wang Y., et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J. Am. Coll. Cardiol. 37:2001;1950-1956
24. Salem S., McDevitt D. Central effects of beta-adrenoceptor antagonists. Clin. Pharmacol. Ther. 33:1983;52-57
25. Houston M.C., Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am. Heart J. 116:1988;515-523
26. Psaty B.M., Koepsell T.D., Wagner E.H., et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA. 263:1990;1653-1657
27. Salpeter S.R., Ormiston T.M., Salpeter E.E., et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir. Med. 97:2003;1094-1101
28. Andrus M.R., Holloway K.P., Clark D.B. Use of beta-blockers in patients with COPD. Ann. Pharmacother. 38:2004;142-145
29. Heintzen M.P., Strauer B.E. Peripheral vascular effects of beta-blockers. Eur. Heart J. 15:1994;2-7
30. Gheorghiade M., Goldstein S. Blockers in the post-myocardial infarction patient. Circulation. 106:2002;394-398
31. Haas S.J., Vos T., Gilbert R.E., et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am. Heart J. 146:2003;848-853
32. Blaufarb I., Pfeifer T.M., Frishman W.H. Beta-blockers: drug interactions of clinical significance. Drug Safety. 13:1995;359-370
33. Van de Werf et al, for the task force of the management of acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003;24:28-66
34. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) ACC/AHA. Guidelines for the management of patients with acute myocardial infarction American College of Cardiology. Available from: www.acc.org September 1999
35. Priori SG, Aliot E, Blomström-Lundqvist C et al. for the Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001;22:1374-450
36. Waagstein F., Hjalmarson Å.C., Wasir H.S. Apex cardiogram and systolic time intervals in acute myocardial infarction and effect of practolol. Br. Heart J. 1974;1109-1121
37. Hjalmarson Å., Elmfeldt D., Herlitz J., et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. ii:1981;823-827
38. Richterova A., Herlitz J., Holmberg S., et al. The Göteborg Metoprolol Trial in Acute Myocardial Infarction. Effects on chest pain. Am. J. Cardiol. 53:1984;32D-6
39. Norris R.M., Brown M.A., Clarke E.D., et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet. 2:1984;883-886
40. ISIS-1 (First International Study of Infarct Survival) collaborative group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;II:57-66
41. The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI). Am J Cardiol 1985;56:1G-57
42. Rydén L., Ariniego R., Arnman K., et al. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N. Engl. J. Med. 308:1983;614-618
43. Yusuf S, Lessem J, Pet J et al. Primary and secondary prevention of myocardial infarction and strokes. An update of randomly allocated controlled trials. J Hypertens 1993;11:(Suppl. 4):S61-S73
44. Freemantle N., Cleland J., Young P., et al. Beta blockade after myocardial infarction. Systematic review and meta regression analysis. BMJ. 1999;1730-1737
45. Roberts R., Rogers W.J., et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction (TIMI) IIB study. Circulation. 83:1991;422-437
46. Van de Werf F., Janssens L., Brzostek T., et al. Short term effect of early intravenous treatment with beta-adrenergic blocking agents or a specific bradycardia agent in patients with acute myocardial infarction receiving thrombolytic therapy. J. Am. Coll. Cardiol. 22:1993;407-416
47. Barron HV, Rundle AC, Gore JM et al. for the Participants in the national registry of myocardial infarction-2. Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator. Am J Cardiol 2000;85:294-8
48. Pfisterer M., Cox J.L., Granger C.G., et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction. The GUSTO-I experience. Global utilization of streptokinase and TPA (alteplase) for occluded coronary arteries. J. Am. Coll. Cardiol. 32:1998;634-640
49. Harjai K.J., Stone G.W., Boura J., et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am. J. Cardiol. 91:2003;655-660
50. Halkin A., Nikolsky E., Aymong E., et al. The survival benefit of periprocedural beta-blockers in patients with acute myocardial infarction undergoing primary angioplasty is determined by use of these drugs before admission. Am. J. Cardiol. 92(Suppl. L):2003;228L
51. Kernis S.J., Arguya K.J., Boura J., et al. Does beta-bloquer therapy improbé clinical outcomes of acute myocardial infarction after successful primary angioplasty?. A pooled análisis from the primary angioplasti in myocardial infarction-2 (PAMI-2), No surgery on-site (noSOS), stetn PAMI and Air PAMI trials. Circulation. 108(Suppl. IV):2003;416-417
52. Wood D, De Backer G, Faergeman O et al. for the Second Joint Task Force of European and other Societies† on Coronary Prevention: European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Network. Prevention of coronary heart disease in clinical practice. Eur. Heart J. 1998;19:1434-1503
53. Gibbons RJ, Chatterjeee K, Daley J et al. for the task force on practice guidelines, ACC/AHA/ACP-ASIM. Guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 1999;33:2092-197
54. Eagle KA, Berger PB, Calkins H et al. for the task force. ACC/AHA guideline update on perioperative cardiovascular evaluation for noncardiac surgery. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2002;105:1257-67
55. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult 2002. Available from: http://www.acc.org
56. Grundy S.M., Ivor J., Benjamin I.J., et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation. 100:1999;1134-1146
57. Smith S.C., Blair S.N., Bonow R.O., et al. AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 104:2001;1577-1579
58. De Backer G, Ambrosioni E, Borch-Johnsen K et al. for the Third Join Task Force of the European and other Societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10
59. Soumerai S.B., McLaughlin T.J., Spiegelman D., et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA. 277:1997;115-121
60. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin: The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS) Eur Heart J 2002;23:1190-201
61. The beta-blocker heart attack study group. The beta-blocker heart attack trial. JAMA 1981;246:2073-4
62. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7
63. Pedersen T.R. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. Engl. J. Med. 313:1985;1055-1058
64. Hjalmarson A., Elmfeldt D., Herlitz J., et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet. 2:1981;823-827
65. Boissel J.P., Leizorovicz A., Picolet H., et al. Secondary prevention after high-risk acute myocardial infarction with low dose acebutolol. Am. J. Cardiol. 66:1990;251-260
66. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction. The CAPRICORN randomised trial. Lancet 2001;357:1385-90
67. The beta-blocker pooling project research group. The beta-blocker pooling project. Subgroup findings from randomized trials in postinfarction patients. Eur Heart J 1988;9:8-16
68. Hedblad J., Wikstrand L., Janzon H., et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the beta-blocker cholesterol-lowering asymptomatic plaque study (BCAPS). Circulation. 103:2001;1721-1726
69. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI study group. Br. Med. J. 314:1997;1512-1515
70. Bertrand ME, Simoons ML, Fox KAA et al. for the task force of the European Society of Cardiology. Management of acute coronary syndromes: acute coronary syndromes without persistent ST-segment elevation. Eur Heart J 2000;21:1406-32
71. Bertrand ME, Simoons ML, Fox KAA et al. for the task force on the management of acute coronary syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809-40
72. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina) ACC/AHA guideline update for the management of patients with unstable angina and non ST-segment elevation myocardial infarction. American Heart Association; 2002. Available from: www.americanheart.org
73. Gottlieb S., Weisfeldt M.L., Ouyang P., et al. Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: a randomized, double-blind, placebo-controlled trial. Circulation. 3:1986;331-337
74. Telford A., Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet. 1:1981;1225-1228
75. Lubsen J.T.J. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am. J. Cardiol. 60:1987;18A-25A
76. Yusuf S., Witte J., Friedman L. Overview of results of randomized trials in heart disease: unstable angina, heart failure, primary prevention with aspirin and risk factor modifications. JAMA. 260:1988;2259-2263
77. Ellis K., Tcheng J.E., Sapp S., et al. Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. J. Interv. Cardiol. 16:2003;299-305
78. Tilmant P.Y., Lablanche J.M., Thieuleux F.A., et al. Detrimental effect of propranolol in patients with coronary arterial spasm countered by combination with diltiazem. Am. J. Cardiol. 52:1983;230-233
79. Task Force of the European Society of Cardiology. Management of stable angina pectoris. Eur Heart J 1997;18:394-413
80. Wang T.J., Stafford R.S. National patterns and predictors of betablocker use in patients with coronary artery disease. Arch. Int. Med. 158:1998;1901-1906
81. Rydén L. Efficacy of epanolol versus metoprolol in angina pectoris: report from a Swedish multicentre study of exercise tolerance. J. Int. Med. 231:1992;7-11
82. Boberg J., Larsen F.F., Pehrsson S.K. The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. The Visacor Study Group. Clin. Cardiol. 15:1992;591-595
83. Frishman W.H., Heiman M., Soberman J., et al. Comparison of celiprolol and propranolol in stable angina pectoris. Celiprolol International Angina Study Group. Am. J. Cardiol. 67:1991;665-670
84. Cruickshank J.M., Prichard B.N.C. Arrhythmias. Cruickshank J.M., Prichard B.N.C. Beta-blockers in clinical practice. 1996;631-704 Churchill Livingstone, London
85. Gruppo italiano per lo studio della sopravvivenza nell-infarto miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22
86. Prida X.E., Hill J.A., Feldman R.L. Systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses. Am. J. Cardiol. 59:1987;1084-1088
87. Capone P., Mayol R. Celiprolol in the treatment of exercise induced angina pectoris. J. Cardiovasc. Pharmacol. 8(Suppl. 4):1986;S135-S137
88. Mulcahy D., Cunningham D., Crean P., et al. Circadian variations of total ischemic burden and its alterations with anti-anginal agents. Lancet. i:1988;755-788
89. Hauf-Zachariou U., Blackwood R.A., Gunawardena K.A., et al. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur. J. Clin. Pharmacol. 52:1997;95-100
90. McLenachan J.M., Findlay I.N., Wilson J.T., et al. Twenty-four hour beta-blockade in stable angina pectoris: a study of atenolol and betaxolol. J. Cardiovasc. Pharmacol. 20:1992;311-315
91. Pepine C.J., Cohn P.F., Deedwania P.C., et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation. 90:1994;762-768
92. Wallace W.A., Wellington K.L., Chess M.A., et al. Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris. Am. J. Cardiol. 73:1994;23-28
93. de Vries R.J., van den Heuvel A.F., Lok D.J., et al. Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands Working Group on Cardiovascular Research (WCN). Int. J. Cardiol. 57:1996;143-150
94. Fox K.M., Mulcahy D., Findlay I., et al. The total ischaemic burden european trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Group. Eur. Heart J. 17:1996;96-103
95. van de Ven L.L., Vermeulen A., Tans J.G., et al. Which drug to choose for stable angina pectoris: a comparative study between bisoprolol and nitrates. Int. J. Cardiol. 47:1995;217-223
96. Waysbort J., Meshulam N., Brunner D. Isosorbide-5-mononitrate and atenolol in the treatment of stable exertional angina. Cardiology. 79(Suppl. 2):1991;19-26
97. Kawanishi D.T., Reid C.L., Morrison E.C., et al. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J. Am. Coll. Cardiol. 19:1992;409-417
98. Meyer T.E., Adanms C., Commerford P. Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina. Cardiovasc. Drugs Ther. 7:1993;909-913
99. Steffensen R., Grande P., Pedersen F., et al. Effects of atenolol and diltiazem on exercise tolerance and ambulatory ischaemia. Int. J. Cardiol. 40:1993;143-153
100. Parameshwar J., Keegan J., Mulcahy D., et al. Atenolol or nicardipine alone is as efficacious in stable angina as their combination: a double blind randomised trial. Int. J. Cardiol. 40:1993;135-141
101. Foale R.A. Atenolol versus the fixed combination of atenolol and nifedipine in stable angina pectoris. Eur. Heart J. 14:1993;1369-1374
102. Rouleau J.L., Talajic M., Sussex B., et al. Myocardial infarction patients in the 1990s - their risk factors, stratification and survival in Canada: the Canadian assessment of myocardial infarction (CAMI) Study. J. Am. Coll. Cardiol. 27:1996;1119-1127
103. Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. Am. J. Cardiol. 61:1988;1219-1222
104. Dargie H.J., Ford I., Fox K.M. Total ischaemic burden european trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur. Heart J. 17:1996;104-112
105. Rehnqvist N., Hjemdahl P., Billing E., et al. Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. angina prognosis study in stockholm. Cardiologia. 40(Suppl. 1):1995;301
106. von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J. Am. Coll. Cardiol. 25:1995;231-238
107. Savonitto S., Ardissiono D., Egstrup K., et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the international multicenter angina exercise (IMAGE) study. J. Am. Coll. Cardiol. 27:1996;311-316
108. Remme WJ, Swedberg K et al for the task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60
109. Komajda M, Follath F, Swedberg K et al. for the study group of diagnosis of the working group on heart failure of the European Society of Cardiology. The Euro heart failure survey programme - a survey on the quality of care among patients with heart failure in Europe: Part 2: treatment, Eur Heart J 2003;24:464-74
110. Waagstein F., Hjalmarson.Ȧ.A., Varnauskas E., et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br. Heart J. 37:1975;1022-1036
111. Swedberg K., Hjalmarson A., Waagstein F., et al. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br. Heart J. 44:1980;117-133
112. Anderson J., Lutz J.R., Gilbert E.M., et al. A randomized trial of low-dose betablockade therapy for idiopathic dilated cardiomyopathy. Am. J. Cardiol. 55:1985;471-475
113. Engelmeier R.S., O'Connell J.B., Walsh R., et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 72:1985;536-546
114. Waagstein F, Bristow MR, Swedberg K,et al. for the MDC Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6
115. CIBIS investigators and committees. A randomized trial of beta-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994;90:1765-73
116. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334:1996;1349-1355
117. Colucci W.S., Packer M., Bristow M.R., et al. for the US carvedilol heart failure study group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806
118. Bristow M.R., Gilbert E.M., Abraham W.T., et al. for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816
119. Australia/New Zealand heart failure research collaborative group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80
120. Lechat P., Packer M., Chalon S., et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 98:1998;1184-1191
121. CIBIS-II investigators and committees. The cardiac insufficiency bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13
122. MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7
123. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. Circulation 2000;101:378-84
124. Packer M., Coats A.J.S., Fowler M.B., et al. for the carvedilol prospective randomized cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344:2001;1651-1658
125. Doughty R.N., Whalley G.A., Gamble G., et al. on behalf of the Australia-New Zealand Heart Failure Research Collaborative Group. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J. Am. Coll. Cardiol. 29:1997;1060-1066
126. Shekelle PG, Rich MW, Morton SC, PHD et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-38
127. Metra M., Giubbini R., Nodari S., et al. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 102:2000;546-551
128. Bolger A.P., Al-Nasser F. Beta-blockers for chronic heart failure: surviving longer but feeling better. Int. J. Cardiol. 92:2003;1-8
129. Goldstein S., Fagerberg B., Hjalmarson Å., et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J. Am. Coll. Cardiol. 38:2001;932-938
130. The beta-blocker evaluation of survival trial investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67
131. Torp-Pedersen C., Køber L., Ball S., et al. The incomplete bucindolol evaluation in acute myocardial infarction trial (BEAT. Eur. J. Heart Fail. 4:2002;495
132. Poole-Wilson P.A., Swedberg K., Cleland J.C.F., et al. for the COMET investigators Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): randomised controlled trial. Lancet. 362:2003;7-13
133. MacMurray J., Cohen-Solal A., Dietz R., et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur. J. Heart Failure. 3:2001;495-502
134. Herlitz J., Waagstein F., Lindqvist J., Swedberg K., Hjalmarson A. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial. Am. J. Cardiol. 80:1997;40J-44J
135. Nieminen M, Böhm M, Germany; Helmut Drexler H et al. for the European Society of Cardiology Task Force on Acute Heart Failure. Guidelines for the diagnosis and treatment of acute heart failure. Eur Heart J (will be submitted to the European Heart Journal in 2004)
136. Fuster V, Rydén LE, Asinger RW et al. for the ACC/ AHA/ESC task force. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001;1852-923
137. Blomström-Lundqvist C., Scheinman M.M., Aliot E.M., et al. ACCC/AHA/ESC Guidelines for he management of patients with supraventricular arrhythmias A report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur. Heart J. 24:2003;1857-1897
138. Turner P., Granville-Grosman K.L., Smart J.V. Effect of adrenergic receptor blockade on the tachycardia of toritoxicosis and anxiety state. Lancet. 2:1965;1316-1318
139. Delarue N.C., Morrow J.D., Kerr J.H., Colapinto R.F. Phaeocromocytoma in the modern context. Can. J. Surg. 21:1978;387-394
140. Singh B.N. Clinical aspects of the antiarrhythmic action of beta-receptor blocking drugs. Part 1. Pattern of response of common arrhythmias. NZ Med. J. 78:1973;482-486
141. Rehnqvist N. Clinical experience with intravenous metoprolol in supraventricular tachyarrhythmias. A multicentre study. Ann. Clin. Res. 13(Suppl. 30):1981;68-72
142. Sweany A.E., Moncloa F., Vickers F.F., et al. Antiarrhythmic effects of intravenous timolol in supraventricular arrhythmias. Clin. Pharmacol. Ther. 37:1985;124-127
143. McBride J.W., McCoy H.G., Goldenberg I.F. Supraventricular tachycardia treated with continuous infusion of propranolol. Clin. Pharmacol. Ther. 44:1988;93-99
144. Jordaens L., Gorgels A., Stroobandt R., et al. Efficacy and safety of intravenous sotalol for the termination of paroximal supraventricular tachycardia. Am. J. Cardiol. 68:1991;35-40
145. Cruickshank J.M., Prichard B.N.C. Arrhythmias. Cruickshank J.M., Prichard B.N.C. Beta-blockers in clinical practice. 1996;705-763 Churchill Livingstone, London
146. Gibson D.G., Sowton E. The use of beta-adrenergic receptor blocking drugs in dysrrhythmias. Prog. Cardiovasc. Dis. 12:1969;16-39
147. Klein G.J., Bashore T.M., Sellers T., et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N. Engl. J. Med. 301:1979;1080-1085
148. Dreifus L.S., Haiat R., Watanabe Y., et al. Ventricular fibrillation: a possible mechanism of sudden cardiac death in patients and Wolff-Parkinson-White syndrome. Circulation. 43:1971;520-527
149. Prystowsky E.N., Benson D.W. Jr., Fuster V., et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 93:1996;1262-1277
150. Steeds R.P., Birchall A.S., Smith M., et al. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart. 82:1999;170-175
151. Kuhlkamp V., Schirdewan A., Stangl K., et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 36:2000;139-146
152. National High Blood Pressure Education Program. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183:S1-S22
153. Platia E.V., Michelson E.L., Porterfield J.K., et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am. J. Cardiol. 63:1989;925-929
154. Lewis R.V., McMurray J., McDevitt D.G. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J. Cardiovasc. Pharmacol. 13:1989;1-6
155. Farshi R., Kistner D., Sarma J.S., et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open label of five drug regimens. J. Am. Coll. Cardiol. 33:1999;304-310
156. Gulamhusein S., Ko P., Klein G.J. Ventricular fibrillation following verapamil in the Wolff-Parkinson-White syndrome. Am. Heart J. 106:1983;145-147
157. Khand A.U., Rankin A.C., Martin W., et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure. J. Am. Coll. Cardiol. 42:2003;1944-1951
158. Balser J.R., Martinez E.A., Winters B.D., et al. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology. 89:1998;1052-1059
159. Plewan A., Lehmann G., Ndrepepa G., et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation;sotalol vs bisoprolol. Eur. Heart J. 22:2001;1504-1510
160. Katritsis D., Panagiotakos D.B., Karvouni E., et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am. J. Cardiol. 92:2003;1116-1119
161. Singh B.N., Jewitt D.E. Beta-adrenoreceptor blocking drugs in cardiac arrhythmias. Cardiovasc. Drugs. 2:1997;119-159
162. Mosca L., Scott M., Grundy S.M., et al. Guide to preventive cardiology for women. AHA/ACC scientific statement. Circulation. 99:1999;2480-2484
163. Priori S.G., Aliot E., Blomström-Lundqvist C., et al. Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur. Heart J. 24:2003;13-15
164. Meltzer L.E., Kitchell J.R. The development and current status of coronary care. En: Textbook of coronary care. Excerpta Medica (Amsterdam). 1972;3-25
165. Milner P.G., Platia E.V., Reid P.R., et al. Ambulatory electrocardiographic recordings at the time of fatal cardiac arrest. Am. J. Cardiol. 56:1985;588-592
166. Marcus F.I., Cobb L.A., Edwards J.E., et al. Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute
167. Farb A., Tang A.L., Burke A.P., et al. Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation. 92:1995;1701-1709
168. Rydén L., Ariniego R., Arnman K., et al. A double blind trial of metoprolol in acute myocardial infarction. N. Engl. J. Med. 308:1983;614-618
169. Rossi P.R., Yusuf S., Ramsdale D., et al. Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction. Br. Med. J. 286:1983;506-510
170. Nuttal S.L., Toescu V., Kendall M.J. Beta-blockade after myocardial infarction. BMJ. 320:2000;581-588
171. Held P. Effects of beta blockers on ventricular dysfunction after myocardial infarction:tolerability and survival effects. Am. J. Cardiol. 71:1993;39C-44
172. Kendall M.J., Lynch K.P., Hjalmarson A., et al. Beta-blockers and sudden cardiac death. Ann. Int. Med. 123:1995;358-367
173. Maron B.J. Hypertrophic cardiomyopathy. Lancet. 350:1997;127-133
174. Spirito P., Seidman C.E., McKenna W.J., et al. The management of hypertrophic cardiomyopathy. N. Engl. J. Med. 336:1997;775-785
175. McKenna W., Deanfield J., Faruqui A., et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and haemodynamic features. Am. J. Cardiol. 47:1981;532-538
176. Maron BJ, McKenna W, Danielson GK, et al for the American College of Cardiology/European Society of Cardiology clinical expert task force. Hypertrophic cardiomyopathy. Eur Heart J 2003 24:1965-91
177. Desseigne P., Tabib A., Loire R. Myocardial bridging on the left anterior descending coronary artery and sudden cardiac death. Apropos of 19 cases with autopsy. Arch. Mal. Coeur Vaiss. 84:1991;511-516
178. Schwarz E.R., Klues H.G., Vom D.J., et al. Functional, angiographic and intracoronary Doppler flow characteristics in symptomatic patients with myocardial bridging: effect of short-term intravenous betablocker medication. J. Am. Coll. Cardiol. 27:1996;1637-1645
179. Schwartz P.J., Priori S.G., Napolitano C. The long QT syndrome. Zipes D.P., Jalife J. Cardiac electrophysiology. From cell to bedside. 2000;597-615 WB Saunders, Philadelphia
180. Moss A.J., Schwartz P.J., Crampton R.S., et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 84:1991;1136-1144
181. Schwartz P.J., Priori S.G., Spazzolini C., et al. Genotype phenotype correlation in the long-QT syndrome: gene specific triggers for life-threatening arrhythmias. Circulation (Online). 103:2001;89-95
182. Coumel P., Fidelle J., Lucet V., et al. Catecholaminergic-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: report of four cases. Br. Heart J. 40:1978;28-37
183. Leenhardt A., Lucet V., Denjoy I., et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 91:1995;1512-1519
184. Myerburg R.J., Kessler K.M., Zaman L., et al. Survivors of prehospital cardiac arrest. JAMA. 247:1982;1485-1490
185. Priori S.G., Crotti L. Idiopathic ventricular fibrillation. Cardiac Electrophysiol. Rev. 3:1999;198-201
186. Brugada P., Brugada J. Right bundle branch block, persistent ST-segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J. Am. Coll. Cardiol. 20:1992;1391-1396
187. Thakkar R.B., Oparil S. What do international guidelines say about therapy. Hypertension. 19(Suppl. 3):2001;S23-31
188. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA. 289:2003;2560-2572
189. Guidelines subcommittee. 1999 World Health Organization-international Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151-8
190. Dahlöf B., Lindholm L.H., Hansson L., et al. Morbidity and mortality in the swidish trial in old patients with hypertension (STOP-Hypertension). Lancet. 338:1991;1281-1285
191. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. Br Med J 1985;291:97-104
192. Olsson G., Tuomilehto J., Berglund G., et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am. J. Hypertens. 4:1991;151-158
193. Psaty B.M., Smith N.L., Siscovick D.S., et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 277:1997;739-745
194. Maphy and the two arms of Happhy. JAMA 1989;262:3272-4
195. Goldstein L.B., Adams R., Becker K., et al. Primary prevention of ischemic stroke. A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation. 103:2001;163-182
196. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;355:1955-64
197. Hansson L, Lindholm LH, Niskanen L et al. for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6
198. Hansson L., Lindholm L.H., Ekbom T., et al. for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderl y patients: cardiovascular mortality and morbidity the Swedish Trial. Lancet. 354:1999;1751-1756
199. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type-2 diabetes-UKPDS-38. BMJ 1998;317:703-13
200. Staessen J.A., Wang J.G., Thijs L. Cardiovascular protection and blood pressure reduction. A meta-analysis. Lancet. 358:2001;1305-1315
201. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. for the LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet. 359:2002;995-1003
202. Erbel R, Alfonso F, Boileau C et al. for the task force of the European Society of Cardiology: Diagnosis and management of aortic dissection. Recommendations of the task force on aortic dissection, European Society of Cardiology. Eur Heart J 2001;22:1642-81
203. DeSanctis R.W., Doroghazi R.M., Austen W.G., et al. Aortic dissection. N. Engl. J. Med. 317:1987;1060-1067
204. Isselbacher E.M. Diseases of the aorta. Braunwald E., Zipes D.P., Libby P. Heart disease. 2001;1422-1456 WB Saunders, Philadelphia
205. Siddiqui A.K., Ahmed S., Delbeau H., Conner D., Mattana J. Lack of physician concordance with guidelines on the perioperative use of beta-blockers. Arch. Int. Med. 164:2004;664-667
206. Magnusson J., Thulin T., Werner O., et al. Haemodynamic effects of pretreatment with metoprolol in hypertensive patients undergoing surgery. Br. J. Anaesth. 58:1986;251-260
207. Stone J.G., Foex P., Sear J.W., et al. Risk of myocardial ischaemia during anaesthesia in treated and untreated hypertensive patients. Br. J. Anaesth. 61:1988;675-679
208. Stone J.G., Foex P., Sear J.W., et al. Myocardial ischaemia in untreated hypertensive patients: effect of a single small oral dose of a beta-adrenergic blocking agent. Anesthesiology. 68:1988;495-500
209. Pasternack P.F., Grossi E.A., Baumann F.G., et al. Beta-blockade to decrease silent myocardial ischaemia during peripheral vascular surgery. Am. J. Surg. 158:1989;113-116
210. Pasternack P.F., Imparato A.M., Baumann F.G., et al. The hemodynamics of beta-blockade in patients undergoing abdominal aortic aneurysm repair. Circulation. 76(Suppl. 3):1987;III-1-7
211. Yeager R.A., Moneta G.L., Edwards J.M., et al. Reducing perioperative myocardial infarction following vascular surgery: the potential role of beta-blockade. Arch. Surg. 130:1995;869-872
212. Raby K.E., Brull S.J., Timimi F., et al. The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. Anesth. Analg. 88:1999;477-482
213. Jakobsen C.J., Bille S., Ahlburg P., et al. Perioperative metoprolol reduces the frequency of atrial fibrillation after thoracotomy for lung resection. J. Cardiothorac. Vasc. Anesth. 11:1997;746-751
214. Bayliff C.D., Massel D.R., Inculet R.I., et al. Propranolol for the prevention of postoperative arrhythmias in general thoracic surgery. Ann. Thorac. Surg. 67:1999;182-186
215. Mangano D.T., Layug E.L., Wallace A., et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. Engl. J. Med. 335:1996;1713-1720
216. Poldermans D., Boersma E., Bax J.J., et al. for the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N. Engl. J. Med. 341:1999;1789-1794
217. Boersma E., Poldermans D., Bax J.J., et al. Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA. 285:2001;1865-1873
218. Wallace A, Layug B, Tateo I et al. for the McSPI Research Group. Prophylactic atenolol reduces postoperative myocardial ischaemia. Anesthesiology. 1998;88:7-17
219. Brignole M., Menozzi C., et al. A controlled trial of acute and long-term medical therapy in tilt-induced neurally mediated syncope. Am. J. Cardiol. 70:1992;339-342
220. Sheldon R., Rose S., Flanagan P., et al. Effects of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test. Am. J. Cardiol. 78:1996;536-539
221. Di Gerolamo E., Di Iorio C., Sabatini P., et al. Effects of different treatments vs no treatment on neurocardiogenic syncope. Cardiologia. 43:1998;833-837
222. Flevari P., Livanis E., Theodorakis G., et al. Neurocardiogenic syncope: prospective, randomized, cross-over evaluation of the effects of propranolol, nadolol and placebo on syncope recurrence and patients' well-being (Abstr.). PACE. 23:2000;666
223. Madrid A., Ortega I., Rebollo G.J., et al. Lack of efficacy of atenolol for the prevention of neurally-mediated syncope in highly symptomatic population: a prospective double-blind, randomized and placebo-controlled study. J. Am. Coll. Cardiol. 37:2001;554-557
224. Fitzpatrick A.P., Ahmed R., Williams S., et al. A randomized trial of medical therapy in malignant vasovagal syndrome or neurally-mediated bradycardia/hypotension syndrome. Eur. J. Cardiac Pacing Electrophysiol. 1:1991;191-202
225. Mahanonda N., Bhuripanyo K., Kangkagate C., et al. Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results. Am. Heart J. 130:1995;1250-1253
226. Brignole M, Alboni P, Benditt D et al. for the Task Force on Syncope, European Society of Cardiology. Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J 2001; 22:1256-306
227. Oakley C, Child A, Iung B et al. for the Task Force on the management of Cardiovascular diseases during pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003;24:761-81
228. Bloomfield T.H., Howkins D.F. The effect of drugs on human fetus. Stechll, Ginsberg Scientific foundations of obstetric and gynecology. 1991;320-336 Butterworth/Heinemann, Oxford
229. Kubo T., Eduardo R., Azevedo, et al. Lack of evidence for peripheral alpha-1 adrenoceptor blockade during long-term treatment of heart failure with carvedilol. J. Am. Coll. Cardiol. 38:2001;1463-1469